Personalised Pharmacotherapy and Model-Informed Precision Dosing in Inflammatory Bowel Disease
Description
This research programme aims to improve the effectiveness, safety and cost-effectiveness of pharmacotherapy for patients with inflammatory bowel disease. We develop and evaluate therapeutic drug monitoring and model-informed precision dosing strategies for immunomodulators and monoclonal antibodies, using population pharmacokinetic models, Bayesian forecasting and remote sampling. Current research includes the rediscovery and optimisation of thioguanine, pharmacogenetics, exposure–response relationships for biologicals, intravenous and subcutaneous infliximab dosing, remote monitoring and implementation within a virtual biologics clinic. The programme also uses real-world data, evidence synthesis and prediction models to support the positioning and individualised use of advanced therapies.
Who is the principal investigator?
Dr. Luc Derijks
Team
Ahmed Bayoumy, PhD candidate
Rianne Weersink, researcher
Clinical pharmacists, pharmacometricians, gastroenterologists, laboratory specialists, data scientists and research students.
Who is collaborating?
Maastricht UMC+/Maastricht University–NUTRIM
Máxima MC
Collaborating academic and teaching hospitals; and partners in pharmacometrics, therapeutic drug monitoring, biosensor technology and digital healthcare.
Relevant links
Population pharmacokinetics of thioguanine
Subcutaneous infliximab dosing simulations
Are we looking for students or researchers to collaborate on this project?
Yes. Opportunities are available for students and researchers interested in pharmacometrics, therapeutic drug monitoring, pharmacogenetics, remote monitoring, biosensor technology, real-world data, external model validation and clinical implementation.
Also, visit our Vacancies page.
Contact for internship or collaboration
Dr. Luc Derijks (luc.derijks@mumc.nl)